Онлайн (Онлайн)ISSN 2313-1519
Баспалық (Печатный) ISSN 1812-2892
Тұжырымдама (Резюме) - Analysis of thyroid carcinomas with immunohistochemical panel application: retrospectively study of 52 cases
[PDF]           
Mecdi Gurhan Balci, Mahir Tayfur

Aim: The aim of this study was to share our cases of thyroid carcinoma with the literature and to emphasize the importance of evaluation with an immunohistochemical panel in cases with difficulty in the differential diagnosis.

Background: Thyroid carcinomas are the most common malignant endocrine tumors. Its incidence is 1% among all cancer. They constitute 0.2% of cancer-related deaths. The papillary carcinoma is the most common group with 70-90%. It has the best prognosis. It is diagnosed by the presence of nuclear features such as the appearance of clarification in the core, the inclusion body, and the core like a groove. Follicular carcinoma is the second most common thyroid tumor with 10-15%. In the differential diagnosis of follicular carcinoma, the capsular invasion and vascular invasion are important. Medullary carcinoma constitutes 3-5% of all thyroid carcinomas. Immunohistochemical stains such as calcitonin, CEA, CK7, chromogranin, synaptophysin, and Congo-Red were applied to confirm the diagnosis of medullary carcinoma. Anaplastic thyroid carcinoma constitutes 1-2% of all thyroid carcinomas. Cellular pleomorphism in the anaplastic carcinoma is higher than that of other thyroid carcinomas.

Results: In this retrospective study, of the 52 thyroid carcinoma cases, 45 (86.6%) were papillary carcinoma, 4 (7.7%) were follicular carcinoma, 2 (3.8%) were anaplastic carcinoma, and 1 (1.9%) was medullary carcinoma.

Conclusion: In the diagnosis of thyroid pathologies, mainly cellular properties are determinative. The evaluation with the immunohistochemical panel will reduce the risk of diagnostic error when the cases that difficultly diagnosed with cellular properties.

Key words: thyroid, carcinoma, immunohistochemistry

 

Corresponding Author: Mahir Tayfur, MD, Assistant Professor, Department of Pathology, Medical Faculty, Erzincan Binali Yıldırım University, Erzincan, Turkey. Tel.: +9005052104975. E-mail: drmahirtayfur@gmail.com

 

REFERENCES

1. Sadullahoğlu C, Sayıner A, Süren D, Yıldırım HT, Nergiz D, Sezer C, Oruç MT. The diagnostic significance of trophoblast cell-surface antigen-2 expression in benign and malignant thyroid lesions. Indian J Pathol Microbiol. 2019; 62(2):206-210. https://doi.org/10.4103/IJPM.IJPM_202_18

2. LiVolsi VA. Papillary thyroid carcinoma: an update. Mod Pathol. 2011; 24(2):1-9. https://doi.org/10.1038/modpathol.2010.129

3. Pellegriti G, Frasca F,  Regalbuto C, Squadrito S, Vigneri R. World wide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212. https://doi.org/10.1155/2013/965212

4. Olson E, Wintheiser  G,  Wolfe KM, Droessler J, Silberstein T. Epidemiology of thyroid cancer: a review of the national cancer database, 2000-2013. Cureus. 2019; 11(2):e4127. https://doi.org/10.7759/cureus.4127

5. Popoveniuc G,  Jonklaas J. Thyroid nodules. Med Clin North Am. 2012; 96(2):329-349. https://doi.org/10.1016/j.mcna.2012.02.002

6. Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A. Overall survival of papillary thyroid carcinoma patients: A single-institution long-term follow-up of 5897 patients. World J Surg. 2018; 42(3):615-622. https://doi.org/10.1007/s00268-018-4479-z

7. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB,  Bigos ST, et al. The impact of age and gender on a papillary thyroid cancer survivor.  J Clin Endocrinol Metab. 2012; 97(6):878-887. https://doi.org/10.1210/jc.2011-2864

8. Kwong N, Medici M, Angell TE, Liu X, Marqusee E, Cibas ES, et al. The influence of patientage on thyroid nodule formation, multinodularity, and thyroid cancer risk. J Clin Endocrinol Metab. 2015; 100(12):4434-4440. https://doi.org/10.1210/jc.2015-3100

9. Clark KJ, Cronan JJ, Scola FH. Color Doppler sonography: anatomic and physiologic assessment of the thyroid. J Clin Ultrasound. 1995; 23:215-223. https://doi.org/10.1002/jcu.1870230403

10. Yeung MJ,  Serpell JW. Management of the solitary thyroid nodule. The Oncologist. 2008; 13(2):105-112. https://doi.org/10.1634/theoncologist.2007-0212

11.Cornett WR, Sharma AK, Day TA, Richardson MS, Hoda RS, van Heerden JA, Fernandes JK. Anaplastic thyroid carcinoma: An overview. Curr Oncol Rep. 2007; 9:152-158. https://doi.org/10.1007/s11912-007-0014-3

12. Shin HJ, Hwang KA, Choi KC. Antitumor effect of various phytochemicals on diverse types of thyroid cancers.  Nutrients. 2019; 11(1). https://doi.org/10.3390/nu11010125

13. Marques P, Leite V, Bugalho MJ. Retrospective analysis of 255 papillary thyroid carcinomas ≤2 cm: clinicohistological features and prognostic factors. Eur Thyroid J. 2014; 3(4):258-263. https://doi.org/10.1159/000369133

14. Kwak JY, Kim EK, Kim JK, et al. Dual primingoligonucleotide-based multiplex PCR analysis for detection of  BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area. HeadNeck. 2010; 32:490-498. https://doi.org/10.1002/hed.21210

15. Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016; 375(11):1054-1067. https://doi.org/10.1056/NEJMra1501993

16. Nikiforov YE, Ohori NP. Papillary carcinoma. In: Nikiforov YE, Biddinger PW, Thompson LDR editors. Diagnostic pathology and molecular genetics of the thyroid: A comprehensive guide for practicing thyroid pathology. 2nd edition. Philadelphia: WolterKluver /Lippincott Williams &Wilkins; 2012; 183-246.

17. Boerner SL, Asa SL. Biopsy interpretation series: Biopsy interpretation of the thyroid. Epstein JI, editor. Philadelphia: WolterKluver /Lippincott Williams &Wilkins; 2009; 267.

18. Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med. 2008; 132(3):359-372. https://doi.org/10.1043/1543-2165(2008)132[359:AOITTN]2.0.CO;2

19. Parameswaran R, Shulin Hu JS, En NM, Tan WB, Yuan NK. Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation. Ann R Coll Surg Engl. 2017; 99(2):151-154. https://doi.org/10.1308/rcsann.2016.0300

20. Zidan J, Kassem S, Kuten A. Follicular carcinoma of the thyroid gland: prognostic factors, treatment, and survival. Am J Clin Oncol. 2000; 23(1):1-5. https://doi.org/10.1097/00000421-200002000-00001

21. Sobrinho-Simoes M, Asa SL, Kroll TG, Nikiforov Y, DeLeillis R, Farid P, et al. In: World Health Organization classification of tumors: pathology and genetics of tumors of endocrine organs. DeLeillis RA, Lloyd RV, Heitz PU, Eng C, editor. Lyon: IARC Press; Follicular Carcinoma. 2004; 67-72.

22. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. https://doi.org/10.3322/caac.20073

23. Wells SA,  Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. The American thyroid association guidelines task force on medullary thyroid carcinoma. Thyroid. 2015; 25(6): 567-610. https://doi.org/10.1089/thy.2014.0335

24. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-upstudy. J Clin Endocrinol Metab. 2008; 93:682-687. https://doi.org/10.1210/jc.2007-1714

25. Machens A, Dralle H. Simultaneous medullary and papillary thyroid cancer: a novel entity? Ann Surg Oncol. 2012; 19:37-44. https://doi.org/10.1245/s10434-011-1795-z

26.Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017; 13(11):644-660. https://doi.org/10.1038/nrendo.2017.76

27. Rivera M, Sang C, Gerhard R, Ghossein R, Lin O. Anaplastic thyroid carcinoma: morphologic findings and PAX-8 expression in cytology specimens. Acta Cytol. 2010; 54(5):668-672. https://doi.org/10.1159/000325230

28. Gietka-Czernel M. The thyroid gland in postmenopausal women: physiology and diseases. Prz Menopauzalny. 2017; 16(2):33-37. https://doi.org/10.5114/pm.2017.68588

29. Sidibé el H. Thyroid diseases in sub-Saharan Africa. Sante. 2007; 17(1):33-39.

30. Do Cao C, Wémeau JL. Current management of thyroid malignancies. Presse Med. 2009; 38(2):210-219. https://doi.org/10.1016/j.lpm.2008.05.018

31. Shah S, Boucai L. Effect of age on response to therapy and mortality in patients with thyroid cancer at high risk of recurrence. J Clin Endocrinol Metab. 2018; 103(2):689-697. https://doi.org/10.1210/jc.2017-02255

32. Robertson B, Parker M, Shepherd L, Panieri E, Cairncross L, Malherbe F, et al. Nodal disease predicts recurrence whereas other traditional factors affect survival in a cohort of South African patients with differentiated thyroid carcinoma. Cancers Head Neck. 2018; 3:10. https://doi.org/10.1186/s41199-018-0037-5

Көлем (Объем) 3, Сан (Число) 53 (2019)